Finota®

Everolimus

Product Information

  • Proprietary Name: Finota®
  • Generic Name: Everolimus
  • Dosage Form: Tablet
  • Strengths: 5 mg, 10 mg
  • Indications: Hormone Receptor-Positive HER2-Negative Breast Cancer, Neuroendocrine Tumors (NET), Renal Cell Carcinoma (RCC), Tuberous Sclerosis Complex (TSC).

Oncology

Finota®

Everolimus is indicated for the treatment of hormone receptor-positive HER2-negative breast cancer, neuroendocrine tumors (NET), renal cell carcinoma (RCC), and tuberous sclerosis complex (TSC).

Ready to get started?

Curious about a specific position? Sign up for it.
© NanoAlvand. All rights reserved. Powered by ِDGN.